This acquisition of licenses, in addition to its own solutions in hormonal products and innovators in injectable minerals, makes it one of the global leaders in reproduction for cattle, pigs and small ruminants.
The operation is part of the expansion plan of Biogénesis Bagó that includes disbursements for US$50 million in plants and acquisitions for the next three years. As part of this plan, last month the company announced the acquisition of the Argentine laboratory Mayors, allowing Biogénesis Bagó to complement its current portfolio of products for companion animals -mainly focused on vaccines- with a set of 23 pharmaceutical products that includes anti-arthritis, antiparasitics, gastric protectors and dermatological solutions.
Now, it has entered into an agreement with Hipra for the purchase and sale of the line of hormonal products, among which the Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser and Esponjavet brands that are already part of the Biogénesis Bagó portfolio stand out.
in search of leadership
Esteban Turic, CEO of Biogénesis Bagó, stated: “This acquisition is aligned with our strategy to generate long-term growth and sustainable value for our customers and shareholders by focusing on segments that the company dominates very well.”
Turic added that “just as Biogénesis Bagó is a global benchmark in vaccines against foot-and-mouth disease, it is now on its way to also become a leader in solutions for animal reproduction, both for the products it offers and for the technical support service to producers and veterinarians that contributes to the sustainable development of livestock in the main markets of the world”.
The companies began the process of transferring the ownership of the marketing and manufacturing licenses. “This process is scheduled to be completed during 2023 and, meanwhile, normal supply is guaranteed in all markets,” said Sebastián Perretta, executive director of Business at Biogénesis Bagó.